Brief: Vaccinex Completes Enrollment In Phase 1B/2 Signal-Ad (Alzheimer’S Disease) Study Of Pepinemab
25/04/2023 13:52
Vaccinex Inc VCNX.O :
* VACCINEX COMPLETES ENROLLMENT IN PHASE 1B/2 SIGNAL-AD
(ALZHEIMER’S DISEASE) STUDY OF PEPINEMAB
* VACCINEX COMPLETES ENROLLMENT IN PHASE 1B/2 SIGNAL-AD
(ALZHEIMER'S DISEASE) STUDY OF PEPINEMAB
* VACCINEX COMPLETES ENROLLMENT IN PHASE 1B/2 SIGNAL-AD
(ALZHEIMER'S DISEASE) STUDY OF PEPINEMAB
* VACCINEX INC - TOPLINE DATA ANTICIPATED IN MID-2024
* VACCINEX INC - TOPLINE DATA ANTICIPATED IN MID-2024
Source text for Eikon: ID:nGNX9ZHcB7
Further company coverage: VCNX.O
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease